Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447235 | 0.85 | KMT2A (0.52) | KMT2AMDM2SMN1; SMN2MDM4TP53 | |
| SCHEMBL12532519 | 0.80 | KMT2A (0.57) | KMT2AMDM2SMN1; SMN2ALDH1A1HDAC3 | |
| SCHEMBL7752815 | 0.79 | KMT2A (0.67) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL574824 | 0.79 | ALDH1A1 (0.47) | KMT2ASMN1; SMN2ALDH1A1HDAC3HDAC1 | |
| SCHEMBL574816 | 0.78 | KMT2A (0.64) | KMT2ATLR2CASP3 | |
| SCHEMBL6512086 | 0.77 | KMT2A (0.49) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL6297130 | 0.77 | KMT2A (0.52) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL8843737 | 0.77 | KMT2A (0.52) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL28823765 | 0.77 | KMT2A (0.68) | KMT2ATLR2CASP3 | |
| SCHEMBL15669323 | 0.77 | KMT2A (0.68) | KMT2ATLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415486-A2 | Conjugates and compositions for cellular delivery | Sirna Therapeutics, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7964578-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | CHEN TONGQIAN | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | ALB, PHAX, HEXA | KMT2A 1090/4885MDM2 1693/4885SMN1; SMN2 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.